A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

  • STATUS
    Recruiting
  • participants needed
    40
  • sponsor
    Eli Lilly and Company
Send
Updated on 19 February 2024
See if I qualify
covid-19
blood test

Summary

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.

Details
Condition Covid 19
Age 18-75 years
Treatment Placebo, LY3819253
Clinical Study IdentifierNCT04411628
SponsorEli Lilly and Company
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Are hospitalized or in the process of being admitted to hospital and have an initial laboratory determination of current COVID-19 infection less than or equal to ()72 hours prior to randomization
Are men or non-pregnant women
Women of childbearing potential must agree to use at least one highly effective form of contraception for the entirety of the study
Agree to the collection of nasopharyngeal swabs and venous blood

Exclusion Criteria

Require mechanical ventilation or anticipated impending need for mechanical ventilation
Received convalescent COVID-19 plasma treatment prior to enrollment
Were resident in a nursing home or long-term care facility immediately prior to current hospitalization
Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product
Have an oxygen saturation (SpO2) less than (<)88 percent (%) while breathing room air at rest at randomization
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

covid-19
blood test

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.